3SBio
三生制药
elsewhere's corpus covers 3SBio (三生制药) only in passing, through two partnership mentions rather than any dedicated profile: in April 2026, Qiming Venture Partners reported that its portfolio company Tigermed signed a strategic cooperation agreement with 3SBio in Shanghai ; and back in May 2021, per 5Y Capital, the AI microbiome drug developer 未知君 reached a co-development deal with 3SBio on a live-biotherapeutic (全菌胶囊) program in kidney disease . That's the extent of the material here — elsewhere doesn't yet have coverage that would support a fuller picture of the company itself.
AI-generated — may contain errors, please verify.
Coverage
Qiming Weekly | Top 10 Updates from Qiming Venture Partners Portfolio Companies Vol.14, 2026.4.21
Staying with you to mark the milestone moments of Qiming Venture Partners' portfolio companies.
Unknown Closes Nearly $100 Million in Series B Funding, Launches AI×BT Strategy
Focused on gut microbiome AI-driven drug discovery, with self-developed drug candidates already in registrational clinical trials.
5Y News | AI Microbiome Drug Developer "Unknown" Closes Nearly $100 Million Series B Financing
Launching a new AI×BT strategy.
